Literature DB >> 16108112

[Ovarian cancer: incidence and mortality in France].

B Trétarre1, L Remontet, F Ménégoz, J Mace-Lesec'h, P Grosclaude, A Buemi, A V Guizard, M Velten, P Arveux, J Peng, E Jougla, F Laffargue, J P Daurès.   

Abstract

OBJECTIVES: To describe the ovarian cancer incidence and mortality trends in France from 1980 to 2000.
MATERIALS AND METHODS: Incidence data were obtained from 9 French departments covered by cancer registries which systematically record all cancers, of which those of the ovary. Mortality data has been provided by INSERM bureau in charge of the analysis of death certificates.
RESULTS: With 4500 incident cases and 3500 deaths for the year 2000 in France, ovarian cancer still shows a poor prognosis. Age adjusted incidence and mortality rates are almost stable over the study period at an annual rate of 9 by 100000 for incidence and 5.5 by 100000 for mortality. However the risk of developing this cancer and the risk of dying from it, steadily decreased for the cohort born in 1930 to 1950, and the beginning of this reduction corresponds exactly to the beginning of oral contraception. We present comparisons between departments and analyze the border-line tumors in parallel with invasive cancers.
CONCLUSION: The cancer of the ovary represents only a small part of female cancers (3.8%) in France and its incidence is stable over time, but its prognosis is very bad.

Entities:  

Mesh:

Year:  2005        PMID: 16108112     DOI: 10.1016/s0368-2315(05)82707-3

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  5 in total

1.  Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.

Authors:  Charlotte Vaysse; Cyril Touboul; Thomas Filleron; Eliane Mery; Eva Jouve; Pierre Leguevaque; Philippe Morice; Eric Leblanc; Denis Querleu
Journal:  J Gynecol Oncol       Date:  2011-03-31       Impact factor: 4.401

2.  Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute.

Authors:  Anne Marszalek; Séverine Alran; Suzy Scholl; Virginie Fourchotte; Corinne Plancher; Christophe Rosty; Jean Philippe Meyniel; Vincent De Margerie; Thierry Dorval; Anne De La Rochefordière; Paul Cottu; Peter Petrow; Xavier Sastre-Garrau; Rémy Jacques Salmon
Journal:  Int J Surg Oncol       Date:  2010-07-25

3.  [A retrospective study of ovarian cancer with a median follow of 42 months].

Authors:  Fanomezantsoa Raherinantenaina; Solonirina Davidà Rakotomena; Nomeharisoa Rodrigue Emile Hasiniatsy; Felantsoa Auberlin Rakototiana; Florine Rafaramino; Hery Nirina Rakoto Ratsimba
Journal:  Pan Afr Med J       Date:  2015-03-09

4.  Total and partial cancer prevalence in the adult French population in 2008.

Authors:  Marc Colonna; Nicolas Mitton; Nadine Bossard; Aurelien Belot; Pascale Grosclaude
Journal:  BMC Cancer       Date:  2015-03-19       Impact factor: 4.430

5.  Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model.

Authors:  Cyril Touboul; Raphael Lis; Halema Al Farsi; Christophe M Raynaud; Mohamed Warfa; Hamda Althawadi; Eliane Mery; Massoud Mirshahi; Arash Rafii
Journal:  J Transl Med       Date:  2013-01-31       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.